Financial Survey: Cerebain Biotech (OTCMKTS:CBBT) and AbCellera Biologics (NASDAQ:ABCL)

AbCellera Biologics (NASDAQ:ABCL) and Cerebain Biotech (OTCMKTS:CBBT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Earnings and Valuation

This table compares AbCellera Biologics and Cerebain Biotech”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$33.05 million	23.04	-$146.40 million	($0.52)	-4.98
Cerebain Biotech	N/A	N/A	N/A	N/A	N/A

Cerebain Biotech has lower revenue, but higher earnings than AbCellera Biologics.

Analyst Ratings

This is a summary of current ratings and recommmendations for AbCellera Biologics and Cerebain Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	0	1	5	0	2.83
Cerebain Biotech	0	0	0	0	N/A

AbCellera Biologics currently has a consensus target price of $14.20, suggesting a potential upside of 448.26%. Given AbCellera Biologics’ higher probable upside, equities analysts plainly believe AbCellera Biologics is more favorable than Cerebain Biotech.

Insider & Institutional Ownership

61.4% of AbCellera Biologics shares are owned by institutional investors. 32.5% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares AbCellera Biologics and Cerebain Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-463.77%	-13.40%	-10.44%
Cerebain Biotech	N/A	N/A	N/A

Summary

AbCellera Biologics beats Cerebain Biotech on 5 of the 8 factors compared between the two stocks.

About AbCellera Biologics

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

About Cerebain Biotech

Cerebain Biotech Corp. is a biomedical company, which engages in the creation and clinical development of a minimally invasive implantable device. It focuses on the discovery of products for the treatment of Alzheimer’s disease utilizing Omentum. The company was founded on December 18, 2007 and is headquartered in Costa Mesa, CA.